
Capsida furthers its deal with AbbVie

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
MannKind delivers record revenue
MannKind, a biotechnology company that develops treatments for diabetes and pulmonary arterial hypertension, delivered a record year for revenue behind its multiple products out in the market. Based in Westlake Village, MannKind generated revenue worth $99.7 million in 2022, up from $75.2 million in 2021. In the fourth quarter, revenue also shot up to $36 Read More →
Arcutis gearing up for active 2023
Arcutis Biotherapeutics generated sales from its first treatment during the fourth quarter of 2022, helping usher in a new era for the company. Based in Westlake Village, Arcutis recognized $3 million in revenue for the quarter that ended Dec. 31, all of it coming from its Zoryve cream aimed to treat plaque psoriasis. For the Read More →
Inogen shares nosedive after poor fourth-quarter earnings
Shares of Goleta-based Inogen have nosedived 32% in the days since the company’s fourth quarter and full-year earnings results. Inogen, a maker of portable oxygen containers, announced on Feb. 23 that it suffered a net loss of $56.6 million for the quarter ended Dec. 31, up substantially from a net loss of $22.8 million in Read More →

Procore aims for lower net loss, continued high growth in 2023

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.